Results 151 to 160 of about 21,216 (279)
Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial [PDF]
We performed a randomized controlled trial in 30 HIV-infected participants to either continue tenofovir/emtricitabine/efavirenz (Continuation Group) or switch to tenofovir/emtricitabine/raltegravir (Switch Group) for 24 weeks.
Dubé, Michael P. +4 more
core
AIM. To evaluate the efficiency and safety of using raltegravir (RAL) twice daily in conjunction with a once-daily fixed dose combination of abacavir (ABC)/lamivudine (3TC) in patients with HIV infection and active tuberculosis who have not previously ...
A V Kravchenko +7 more
doaj
Time taken to reach undetectable viral loads in therapy-naïve HIV patients commencing ART [PDF]
Peer reviewedPublisher ...
Baguley, Steve +5 more
core
Decreased PD-1 Expression on CD8 Lymphocyte Subsets and Increase in CD8 Tscm Cells in Children with HIV Receiving Raltegravir [PDF]
Florin Tuluc +8 more
openalex +1 more source
Raltegravir‐induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: implications for clinical practice and patient safety [PDF]
Meo Perry +5 more
openalex +1 more source
Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial [PDF]
Nolwenn Hall +56 more
openalex +1 more source

